Navigation Links
OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
Date:3/11/2009

recently submitted the protocol to the FDA for an SPA featuring pain palliation as the primary endpoint. Other Pipeline Highlights - OncoGenex completed patient enrollment in the portion of the Phase 1 clinical trial evaluating the safety of OGX-427 as a monotherapy in patients with solid tumors. - OncoGenex completed the Phase 1 clinical trial evaluating the safety of SN2310 in patients with advanced cancer. Corporate Highlights - Concurrent with the closing of the reverse takeover of Sonus, OncoGenex implemented an immediate workforce reduction of 49% in order to effectively utilize cash assets, while preserving the resources we believe are necessary to advance our priority clinical programs. The Company currently has 26 full-time employees. - In July 2008, OncoGenex increased its economic interest in the OGX- 011 development program and assumed full responsibility for the development of OGX-011 through an amended development agreement with Isis Pharmaceuticals, Inc. - In August 2008, the Company signed an exclusive in-licensing agreement with Bayer HealthCare LLC for development of a family of compounds known as caspase activators presently in preclinical research. As the caspase family of proteases plays essential roles in apoptosis, the caspase activators offer the potential for the development of therapies in the treatment of various cancers.

Conference Call Today at 4:30 p.m. ET

OncoGenex management will host a conference call at 4:30 p.m. Eastern Time today, Wednesday, March 11, 2009, to provide a business update and discuss the fourth quarter and fiscal year 2008 results. A live webcast and slide presentation will be available through the Events and Presentations Web page found in the Investor Relations section
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... July 11, 2014 /CNW/ - Sunovion Pharmaceuticals Canada Inc. ... (eslicarbazepine acetate) for use as a once-daily adjunctive ... with epilepsy who are not satisfactorily controlled with conventional ... in patients under 18 years of age. ... disorders and according to Epilepsy Canada, it affects 0.6% ...
(Date:7/10/2014)... Ouagadougou, Burkina Faso (PRWEB) July 10, 2014 ... Burkina Faso, today have access to an additional ... to increase access to contraception at all levels ... combining a lower-dose formulation of a widely used ... injection system. , Burkina Faso is the first ...
(Date:7/10/2014)... Understanding the need for better quality ... the gap that currently exists in this area, ChanTest ... portfolio of validated ion channel and GPCR cell lines. ... as ion channels control many critical physiological functions throughout ... the potential to treat a variety of human diseases. ...
(Date:7/10/2014)... Robert Harman, DVM, Founder and CEO of ... to announce the relaunch of his highly informative blog, now ... called “ What are Stem Cells ?” Dr. Harman’s ... foundation in the basics of stem cell therapy so that ... type of treatment when considering regenerative medicine. , A veterinarian ...
Breaking Biology Technology:Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3
... 2011 Emerson Ecologics, LLC, the leading provider ... market, today announced that the company has expanded ... for their full product line of nutritional supplements. ... reversing chronic illness and improving health through science-based ...
... July 13, 2011 Reportlinker.com announces that ... in its catalogue: Industrial ... http://www.reportlinker.com/p0570053/Industrial-Biotechnology-China-News-1106.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Renewable_energy In this ... policy and regulation about biofuel, which include ...
... AMSTERDAM, July 12, 2011 , ... technical and,medical information products and services, today ... SciVal Strata,( http://www.info.scival.com/strata ),a web-based tool focused ... offers researchers and research administrators the,flexibility to ...
Cached Biology Technology:Emerson Ecologics Expands Partnership With Metagenics, Announces National Distribution Agreement 2Emerson Ecologics Expands Partnership With Metagenics, Announces National Distribution Agreement 3Industrial Biotechnology China News 1106 2Industrial Biotechnology China News 1106 3Industrial Biotechnology China News 1106 4Elsevier Integrates New Collaboration Analysis Capabilities Into SciVal Strata to Further Enhance Research Evaluation 2Elsevier Integrates New Collaboration Analysis Capabilities Into SciVal Strata to Further Enhance Research Evaluation 3
(Date:7/11/2014)... The Chinese University of Hong Kong, BGI and other ... to salt tolerance, with implication for improving this important ... online in Nature Communications provides an effective ... , Soybean is an important crop for the world. ... less genetic diversities than their wild counterparts. Among the ...
(Date:7/11/2014)... group members to reduce aggression and gain access to ... grooming activities shows a certain pattern across the day. ... Biology Letters . , Grooming between individuals in ... motives. To be groomed has hygienic benefits and is ... can provide access to infants, mating opportunities and high ...
(Date:7/11/2014)... two different ways that allow unprecedented experimental insights ... of oxygen molecules in photosynthesis. The two studies ... Nature Communications . , "The new knowledge will ... oxidation, which are key components for building artificial ... energy in fuels like hydrogen, ethanol or methanol," ...
Breaking Biology News(10 mins):BGI reports a novel gene for salt tolerance found in wild soybean 2Baboons groom early in the day to get benefits later 2Molecular snapshots of oxygen formation in photosynthesis 2
... at Chapel Hill shows how a protein may be crucial ... protein, called "eed," is needed for an essential chemical modification ... findings appear in the May 24 issue of the journal ... a new wave of thinking in genetics: that not all ...
... most, the mere mention of the word "virus" stirs ... suffering. But in recent years, scientists have been trying ... the fight against cancer. , Through genetic engineering, viruses ... abilities to infiltrate, commandeer, replicate and destroy, but only ...
... Howard Hughes Medical Institute have succeeded in mapping the ... range of odors, including vanilla, skunk, fish, urine, musk, ... of neural activity represents a significant step in understanding ... in the nose into odor perception in the brain, ...
Cached Biology News:Protein helps regulate the genes of embryonic stem cells 2Turning viruses into allies against cancer 2Turning viruses into allies against cancer 3Turning viruses into allies against cancer 4Decoding the logic of olfaction 2Decoding the logic of olfaction 3Decoding the logic of olfaction 4
... introduced the highly potent TURBO DNase (patent pending) ... was set in DNA removal capabilities. TURBO DNase ... that is much more efficient than wild type ... unwanted DNA. TURBO DNase binds DNA substrates 6-fold ...
... IEC Centra CL3 series is designed ... research and clinical applications at a ... package includes quick connect rotors and ... yet intuitive interface allows you to ...
Porcine Pulmonary Artery Endothelial Cells (PPAEC) (>500,000 cells)...
... DNA Polymerase I Large (Klenow) Fragment, Exonuclease ... lacks both the 5´→3´ and the 3´→5´ ... DNA Polymerase I (1,2). It is used ... strand displacement amplification (5). Klenow Fragment, Exonuclease ...
Biology Products: